Sarepta Therapeutics (SRPT) Other Non-Current Liabilities (2012 - 2026)
Sarepta Therapeutics' quarterly Other Non-Current Liabilities came in at $1.6 million in Q1 2026, down 96.53% year-on-year from $47.4 million in Q1 2025, and up 7.72% quarter-over-quarter from $1.5 million in Q4 2025.
Sarepta Therapeutics has reported Other Non-Current Liabilities for 15 years, with the latest figure at $1.6 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities fell 96.53% year-over-year to $1.6 million; the trailing twelve-month figure through Mar 2026 stood at $1.6 million (down 96.53% YoY), and the FY2025 full-year result was $1.5 million, down 96.77% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $1.6 million, up from $1.5 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $48.2 million in Q2 2024, with the low at $1.4 million in Q3 2025.
- Average Other Non-Current Liabilities over 5 years is $32.9 million, with a median of $38.1 million recorded in 2023.
- Peak annual rise in Other Non-Current Liabilities reached 530.15% in 2025, while the deepest fall reached 97.04% in 2025.
- Tracing SRPT's Other Non-Current Liabilities over 5 years: stood at $36.9 million in 2022, then grew by 3.25% to $38.1 million in 2023, then climbed by 24.41% to $47.4 million in 2024, then sank by 96.77% to $1.5 million in 2025, then grew by 7.72% to $1.6 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $1.6 million (Q1 2026), $1.5 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Sarepta Therapeutics | 1.86 Bn | 1.17 Bn | 291.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.65 Mn |
| Dec 31, 2025 | 1.53 Mn |
| Sep 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | 47.40 Mn |
| Mar 31, 2025 | 47.40 Mn |
| Dec 31, 2024 | 47.40 Mn |
| Sep 30, 2024 | 47.40 Mn |
| Jun 30, 2024 | 48.20 Mn |
| Mar 31, 2024 | 7.52 Mn |
| Dec 31, 2023 | 38.10 Mn |
| Sep 30, 2023 | 38.10 Mn |
| Jun 30, 2023 | 36.10 Mn |
| Mar 31, 2023 | 36.90 Mn |
| Dec 31, 2022 | 36.90 Mn |
| Sep 30, 2022 | 36.90 Mn |
| Jun 30, 2022 | 43.60 Mn |
| Mar 31, 2022 | 43.60 Mn |
| Dec 31, 2021 | 43.60 Mn |
| Sep 30, 2021 | 43.60 Mn |
| Jun 30, 2021 | 50.80 Mn |
| Mar 31, 2021 | 50.80 Mn |
| Dec 31, 2020 | 50.80 Mn |
| Sep 30, 2020 | 50.50 Mn |
| Jun 30, 2020 | 10.25 Mn |
| Mar 31, 2020 | 5.20 Mn |
| Dec 31, 2019 | 5.20 Mn |
| Sep 30, 2019 | 5.20 Mn |
| Jun 30, 2019 | 5.25 Mn |
| Mar 31, 2019 | 48,000.00 |
| Dec 31, 2018 | 15.56 Mn |
| Sep 30, 2018 | 13.22 Mn |
| Jun 30, 2018 | 13.50 Mn |
| Mar 31, 2018 | 4.96 Mn |
| Dec 31, 2017 | 5.54 Mn |
| Sep 30, 2017 | 6.11 Mn |
| Jun 30, 2017 | 6.41 Mn |
| Mar 31, 2017 | 5.42 Mn |
| Dec 31, 2016 | 5.95 Mn |
| Sep 30, 2016 | 5.26 Mn |
| Jun 30, 2016 | 5.57 Mn |
| Mar 31, 2016 | 5.87 Mn |
| Dec 31, 2015 | 6.17 Mn |
| Sep 30, 2015 | 6.45 Mn |
| Jun 30, 2015 | 6.72 Mn |
| Dec 31, 2014 | 6.78 Mn |
| Jun 30, 2014 | 6.46 Mn |
| Mar 31, 2014 | 7.12 Mn |
| Dec 31, 2013 | 9.01 Mn |
| Dec 31, 2012 | 760,000.00 |